For instance, a recent meta-analysis on patients with inflammatory bowel disease (IBD) and cancer found that almost 40% experienced IBD relapse during ICI inhibitor treatment, with CTLA-4 inhibitor use being associated with a higher risk. This evidence concerns the gene CTLA4 and inflammatory bowel disease.